vs

Side-by-side financial comparison of Live Oak Bancshares, Inc. (LOB) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Live Oak Bancshares, Inc. is the larger business by last-quarter revenue ($145.5M vs $75.5M, roughly 1.9× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 18.4%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.7%).

Live Oak Bank, a subsidiary of Live Oak Bancshares, Inc., is an American bank. Headquartered in Wilmington, North Carolina, it serves small business owners in all 50 states and was the leading SBA 7(a) lender by dollar volume in 2022.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

LOB vs PBYI — Head-to-Head

Bigger by revenue
LOB
LOB
1.9× larger
LOB
$145.5M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+9.4% gap
PBYI
27.7%
18.4%
LOB
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
7.7%
LOB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LOB
LOB
PBYI
PBYI
Revenue
$145.5M
$75.5M
Net Profit
$27.9M
Gross Margin
69.3%
Operating Margin
22.7%
Net Margin
19.2%
Revenue YoY
18.4%
27.7%
Net Profit YoY
187.6%
EPS (diluted)
$0.60
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LOB
LOB
PBYI
PBYI
Q1 26
$145.5M
Q4 25
$161.9M
$75.5M
Q3 25
$146.1M
$54.5M
Q2 25
$143.7M
$52.4M
Q1 25
$126.1M
$46.0M
Q4 24
$116.9M
$59.1M
Q3 24
$129.9M
$80.5M
Q2 24
$125.5M
$47.1M
Net Profit
LOB
LOB
PBYI
PBYI
Q1 26
$27.9M
Q4 25
$46.2M
Q3 25
$26.5M
$8.8M
Q2 25
$23.4M
$5.9M
Q1 25
$9.7M
$3.0M
Q4 24
$9.9M
Q3 24
$13.0M
$20.3M
Q2 24
$27.0M
$-4.5M
Gross Margin
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Operating Margin
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
38.2%
22.7%
Q3 25
25.0%
17.6%
Q2 25
21.7%
12.7%
Q1 25
10.4%
8.7%
Q4 24
11.3%
22.6%
Q3 24
13.7%
27.4%
Q2 24
28.7%
-4.6%
Net Margin
LOB
LOB
PBYI
PBYI
Q1 26
19.2%
Q4 25
28.5%
Q3 25
18.1%
16.2%
Q2 25
16.3%
11.2%
Q1 25
7.7%
6.5%
Q4 24
8.5%
Q3 24
10.0%
25.2%
Q2 24
21.5%
-9.6%
EPS (diluted)
LOB
LOB
PBYI
PBYI
Q1 26
$0.60
Q4 25
$0.96
$0.26
Q3 25
$0.55
$0.17
Q2 25
$0.51
$0.12
Q1 25
$0.21
$0.06
Q4 24
$0.22
$0.40
Q3 24
$0.28
$0.41
Q2 24
$0.59
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LOB
LOB
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$1.3B
$130.3M
Total Assets
$15.3B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Total Debt
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Stockholders' Equity
LOB
LOB
PBYI
PBYI
Q1 26
$1.3B
Q4 25
$1.2B
$130.3M
Q3 25
$1.2B
$115.3M
Q2 25
$1.1B
$104.7M
Q1 25
$1.0B
$97.1M
Q4 24
$999.0M
$92.1M
Q3 24
$1.0B
$71.1M
Q2 24
$961.0M
$48.5M
Total Assets
LOB
LOB
PBYI
PBYI
Q1 26
$15.3B
Q4 25
$15.1B
$216.3M
Q3 25
$14.7B
$202.9M
Q2 25
$13.8B
$194.9M
Q1 25
$13.6B
$196.2M
Q4 24
$12.9B
$213.3M
Q3 24
$12.6B
$220.7M
Q2 24
$11.9B
$205.0M
Debt / Equity
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LOB
LOB
PBYI
PBYI
Operating Cash FlowLast quarter
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
$158.2M
$14.4M
Q3 25
$62.3M
$9.7M
Q2 25
$49.2M
$14.1M
Q1 25
$-33.0M
$3.6M
Q4 24
$156.8M
$15.6M
Q3 24
$47.4M
$11.0M
Q2 24
$29.5M
$1.0M
Free Cash Flow
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
$143.5M
$14.4M
Q3 25
$60.6M
$9.7M
Q2 25
$47.8M
$14.1M
Q1 25
$-35.3M
$3.6M
Q4 24
$107.5M
$15.6M
Q3 24
$41.0M
$11.0M
Q2 24
$12.3M
$1.0M
FCF Margin
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
88.6%
19.1%
Q3 25
41.4%
17.7%
Q2 25
33.3%
26.8%
Q1 25
-28.0%
7.7%
Q4 24
91.9%
26.4%
Q3 24
31.6%
13.7%
Q2 24
9.8%
2.1%
Capex Intensity
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
9.1%
0.0%
Q3 25
1.2%
0.0%
Q2 25
1.0%
0.0%
Q1 25
1.8%
0.1%
Q4 24
42.2%
0.0%
Q3 24
4.9%
0.0%
Q2 24
13.7%
0.0%
Cash Conversion
LOB
LOB
PBYI
PBYI
Q1 26
Q4 25
3.42×
Q3 25
2.35×
1.10×
Q2 25
2.10×
2.41×
Q1 25
-3.39×
1.21×
Q4 24
15.84×
Q3 24
3.64×
0.54×
Q2 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons